Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Philippines to get 30 mln doses of Novavax COVID-19 vaccine - minister

Published 12/21/2020, 03:08 PM
Updated 12/21/2020, 03:10 PM
© Reuters
SVA
-
ARCT
-

MANILA, Dec 21 (Reuters) - The Philippines expects to
receive 30 million doses of Novavax Inc's COVID-19 vaccine by
July next year, its foreign minister said on Monday, boosting
the country's effort to secure supplies to inoculate more than
100 million people.
Despite consultations with numerous vaccine makers, the
Philippines has so far signed only one supply deal, with the
help of its private sector, to acquire 2.6 million shots of a
vaccine developed by AstraZeneca.
It plans to buy 25 million doses of a vaccine from China's
Sinovac Biotech SVA.O for delivery by March and aims to secure
between four and 25 million doses of vaccines from Moderna and
Arcturus Therapeutics Holdings Inc ARCT.O . "Thirty million dosages of the Indian-made Novavax vaccines
are assured possibly with no cash advance. It will be available
by July 2021," Foreign Affairs Secretary Teodoro Locsin said in
an interview with CNN Philippines.
He said the information came from Serum Institute of India,
the world's largest vaccine producer, and that the terms of the
supply deal may be signed before the end of the year.
There was no immediate comment from the institute, which in
August entered a supply and license agreement with Novavax Inc
for the development and commercialization of its COVID-19
vaccine candidate.
Talks with Moderna, which has been granted emergency use
authorisation by the U.S. Food and Drug Administration, will
begin next week, Locsin said.
With 459,789 infections and 8,947 deaths, the Philippines
has recorded the second-highest number of COVID-19 infections
and casualties in Southeast Asia after Indonesia.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.